Both amylin- and GLP-1-based pharmacotherapies have been separately examined preclinically in the context of combinatorial therapies for obesity treatment with other hormonal systems (e. g; leptin, glucagon, glucose dependent insulinotropic peptide)6,39–42; however, there is a surprising paucity of reports systematically examining the hypothesis that combined amylin and GLP-1 therapies may provide enhanced suppression in food intake and body weight43,44. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.